These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 2971403

  • 1. Clodronate for osteolytic metastases due to breast cancer.
    Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, Borgström GH.
    Biomed Pharmacother; 1988; 42(2):111-6. PubMed ID: 2971403
    [Abstract] [Full Text] [Related]

  • 2. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
    Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgström GH.
    Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
    [Abstract] [Full Text] [Related]

  • 3. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E.
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [Abstract] [Full Text] [Related]

  • 4. [Value of Clodronate in the treatment of bone metastasis].
    Pouillart P, Beuzeboc P.
    Bull Cancer; 1991 Jul; 78(8):737-41. PubMed ID: 1834287
    [Abstract] [Full Text] [Related]

  • 5. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
    Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE.
    Cancer; 2004 Jan 01; 100(1):36-43. PubMed ID: 14692022
    [Abstract] [Full Text] [Related]

  • 6. [Dichloromethylene diphosphonate (Cl2MDP) treatment of hypercalcaemia produced from bone metastases (author's transl)].
    Delmas P, Chapuy MC, Vignon E, Briançon D, Charhon S, Meunier PJ.
    Nouv Presse Med; 1982 Apr 24; 11(19):1471-4. PubMed ID: 6210878
    [Abstract] [Full Text] [Related]

  • 7. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A, Chantraine A, Donath A, van Ouwenaller C, Turnill D, Mermillod B, Kitler ME.
    N Engl J Med; 1983 Jun 23; 308(25):1499-501. PubMed ID: 6222257
    [Abstract] [Full Text] [Related]

  • 8. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
    Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, Pancotti A, Di Furia L, Carle F, Cellerino R.
    J Exp Clin Cancer Res; 1998 Jun 23; 17(2):213-7. PubMed ID: 9700583
    [Abstract] [Full Text] [Related]

  • 9. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
    Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G.
    N Engl J Med; 1998 Aug 06; 339(6):357-63. PubMed ID: 9691101
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [The effect of clodronate on bone density in patients with multiple myeloma--a 2-year follow-up of therapeutic effects].
    Adam Z, Prokes B, Znojĭl V, Vorlícek J, Hejlová N, Hájek D, Krejcí M.
    Vnitr Lek; 1996 Jun 06; 42(6):379-85. PubMed ID: 8928406
    [Abstract] [Full Text] [Related]

  • 12. Dichloromethylene diphosphonate action in hematologic and other malignancies.
    Canfield RE, Siris ES, Jacobs TP.
    Bone; 1987 Jun 06; 8 Suppl 1():S57-62. PubMed ID: 2961356
    [Abstract] [Full Text] [Related]

  • 13. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH, Kanis JA, Powles TJ, McCloskey E, Hanson J, Ashley S.
    Can J Oncol; 1995 Dec 06; 5 Suppl 1():54-7. PubMed ID: 8853526
    [Abstract] [Full Text] [Related]

  • 14. Treatment of malignant hypercalcaemia with clodronate.
    Percival RC, Paterson AD, Yates AJ, Beard DJ, Douglas DL, Neal FE, Russell RG, Kanis JA.
    Br J Cancer; 1985 May 06; 51(5):665-9. PubMed ID: 3158326
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y.
    Cancer J; 2001 May 06; 7(5):377-87. PubMed ID: 11693896
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.
    J Clin Oncol; 2006 Oct 20; 24(30):4895-900. PubMed ID: 17001071
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
    Elomaa I, Blomqvist C, Gröhn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmström T.
    Lancet; 1983 Jan 22; 1(8317):146-9. PubMed ID: 6130197
    [Abstract] [Full Text] [Related]

  • 20. [Double-blind trial of oral clodronate in breast cancer patients with bone metastases].
    Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S.
    Bull Cancer; 1993 Jan 22; 80(10 Suppl):50-6. PubMed ID: 8081032
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.